A detailed history of Farther Finance Advisors, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 160 shares of ALLO stock, worth $363. This represents 0.0% of its overall portfolio holdings.

Number of Shares
160
Previous 160 -0.0%
Holding current value
$363
Previous $373,000 20.11%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$2.23 - $4.38 $227 - $446
-102 Reduced 38.93%
160 $373,000
Q1 2024

May 13, 2024

SELL
$2.92 - $5.63 $163 - $315
-56 Reduced 17.61%
262 $1.15 Million
Q4 2023

Feb 14, 2024

BUY
$2.28 - $3.5 $725 - $1,113
318 New
318 $1.02 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.